These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9829861)
1. Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. Keller T; Bitterlich N; Hilfenhaus S; Bigl H; Löser T; Leonhardt P J Cancer Res Clin Oncol; 1998; 124(10):565-74. PubMed ID: 9829861 [TBL] [Abstract][Full Text] [Related]
2. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515 [TBL] [Abstract][Full Text] [Related]
3. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
4. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710 [TBL] [Abstract][Full Text] [Related]
5. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
6. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
7. Detection of lung cancer in silicosis patients using a tumor-marker panel. Schneider J Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960 [TBL] [Abstract][Full Text] [Related]
8. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients. Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786 [TBL] [Abstract][Full Text] [Related]
9. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
10. [Diagnostic significance of the tumor markers CEA, SCC and NSE in serum and bronchoalveolar lavage]. von Eiff M; Koch O; Appelhans N; Roos N; van de Loo J Pneumologie; 1990 Feb; 44 Suppl 1():462-4. PubMed ID: 2164198 [TBL] [Abstract][Full Text] [Related]
11. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions. Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma. Rapellino M; Niklinski J; Pecchio F; Furman M; Baldi S; Chyczewski L; Ruffini E; Chyczewska E Eur Respir J; 1995 Mar; 8(3):407-10. PubMed ID: 7540561 [TBL] [Abstract][Full Text] [Related]
15. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer. Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061 [TBL] [Abstract][Full Text] [Related]
16. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma]. Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253 [TBL] [Abstract][Full Text] [Related]
17. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE]. Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038 [TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234 [TBL] [Abstract][Full Text] [Related]
20. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]